At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis
In Brief
A Phase 3 clinical trial evaluating ABP 798, Rituximab (US), and 1 other intervention for Arthritis, Rheumatoid. Completed, enrolled 311 participants across 55 sites in 6 countries.
Detailed Summary
This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with moderate or severe RA. This study will also assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine.
Study Details
Timeline
Interventions
Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
Supplied as a 10 mg/mL liquid concentrate for IV administration.
Supplied as a 10 mg/mL liquid concentrate for IV administration.